Centre De Recherche Clinique Portes Du Sud — Clinical Trial Site

18 Registered trials

5 Currently recruiting

Organisation

Centre De Recherche Clinique Portes Du Sud

Location

Venissieux, France

Identifier

ORG-100042511

Address

2 Avenue Du 11 Novembre 1918, 69200, France

Departments

Consultation endocrinologie diabétologie
Diabetologie
Diabetology
Endocrinology Diabetology
Hepatology and Gastroenterology
N/A
Service d'Endocrinologie

Clinical trials at this site (18)

Search interface

AMAZE 1: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight lose weight Recruiting

2024-520440-42-00 Obesity 5 2026-05-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

2025-522674-36-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2026-03-24
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting

2023-509912-27-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2024-11-07
Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting

2023-510395-31-00 Metabolic Dysfunction-Associated Steatohepatitis (MASH) 5 2024-10-30
Weight loss in people living with overweight or obesity following treatment with cagrilintide Ended

2024-519530-24-00 Overweight and obesity 5 2025-10-31
A research study to investigate the effects of CagriSema compared to placebo in people with type 2 diabetes and painful diabetic peripheral … Ended

2023-509662-38-00 Type 2 diabetes and painful diabetic peripheral neuropa 4 2025-01-22
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat… Ended

2023-508170-28-00 alcohol-related liver disease 4 2024-08-07
A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended

2023-505857-42-00 Chronic Kidney Disease, Type 2 diabetes 4 2024-04-19
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended

2022-503022-13-00 Hypertriglyceridemia, Cardiovascular Diseases, Atherosc 5 2023-06-08
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended

2022-500101-41-00 Type 2 Diabetes 6 2023-06-07
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
Research study on whether a combination of 2 medicines (NNC0194-0499 and Semaglutide) works in people with non-alcoholic steatohepatitis (NA… Ended

2023-506961-74-00 Non-alcoholic steatohepatitis (NASH) 4 2021-08-31
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19